These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 38702761)

  • 1. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
    Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
    Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
    Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
    Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.
    Zilli T; Scorsetti M; Zwahlen D; Franzese C; Förster R; Giaj-Levra N; Koutsouvelis N; Bertaut A; Zimmermann M; D'Agostino GR; Alongi F; Guckenberger M; Miralbell R
    Radiat Oncol; 2018 Sep; 13(1):166. PubMed ID: 30180867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.
    Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
    Radiother Oncol; 2023 Apr; 181():109503. PubMed ID: 36754232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
    Fredman E; Icht O; Moore A; Bragilovski D; Kindler J; Golan S; Limon D
    BMC Cancer; 2024 Apr; 24(1):431. PubMed ID: 38589860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.
    Yasar B; Suh YE; Chapman E; Nicholls L; Henderson D; Jones C; Morrison K; Wells E; Henderson J; Meehan C; Sohaib A; Taylor H; Tree A; van As N
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):49-58. PubMed ID: 38499253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
    Marciscano AE; Wolfe S; Zhou XK; Barbieri CE; Formenti SC; Hu JC; Molina AM; Nanus DM; Nauseef JT; Scherr DS; Sternberg CN; Tagawa ST; Nagar H
    BMC Cancer; 2023 Aug; 23(1):781. PubMed ID: 37608258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial.
    Ristau J; Hörner-Rieber J; Buchele C; Klüter S; Jäkel C; Baumann L; Andratschke N; Garcia Schüler H; Guckenberger M; Li M; Niyazi M; Belka C; Herfarth K; Debus J; Koerber SA
    Radiat Oncol; 2022 Apr; 17(1):75. PubMed ID: 35428327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
    Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
    Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
    BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring.
    Lee YYD; Nguyen DT; Moodie T; O'Brien R; McMaster A; Hickey A; Pritchard N; Poulsen P; Tabaksblat EM; Weber B; Worm E; Pryor D; Chu J; Hardcastle N; Booth J; Gebski V; Wang T; Keall P
    BMC Cancer; 2021 May; 21(1):494. PubMed ID: 33941111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.
    Devlin L; Dodds D; Sadozye A; McLoone P; MacLeod N; Lamb C; Currie S; Thomson S; Duffton A
    Br J Radiol; 2020 Apr; 93(1108):20190789. PubMed ID: 31971829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE).
    Diven M; Ballman K; Marciscano A; Barbieri C; Piscopo J; Wang S; Nagar H; McClure T
    BMC Urol; 2024 Jul; 24(1):151. PubMed ID: 39054460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.
    Hafeez S; Warren-Oseni K; McNair HA; Hansen VN; Jones K; Tan M; Khan A; Harris V; McDonald F; Lalondrelle S; Mohammed K; Thomas K; Thompson A; Kumar P; Dearnaley D; Horwich A; Huddart R
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1022-30. PubMed ID: 27026308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
    Alayed Y; Davidson M; Liu S; Chu W; Tseng E; Cheung P; Vesprini D; Cheung H; Morton G; Musunuru HB; Ravi A; Korol R; Deabreu A; Ho L; Commisso K; Bhounr Z; D'Alimonte L; Mittmann N; Dragomir A; Zhang L; Loblaw A
    Int J Radiat Oncol Biol Phys; 2020 May; 107(1):136-142. PubMed ID: 31987962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
    Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
    BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.
    Wahl M; Descovich M; Shugard E; Pinnaduwage D; Sudhyadhom A; Chang A; Roach M; Gottschalk A; Chen J
    Technol Cancer Res Treat; 2017 Apr; 16(2):178-187. PubMed ID: 27199276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.